Arcellx, Inc. (ACLX) SEC Filing 8-K Material Event for the period ending Saturday, February 12, 2022

Arcellx, Inc.

CIK: 1786205 Ticker: ACLX

View differences made from one to another to evaluate Arcellx, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Arcellx, Inc..


Assess how Arcellx, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Arcellx, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: ACLX
CIK: 1786205
Form Type: 8-K Corporate News
Accession Number: 0001193125-22-044879
Submitted to the SEC: Thu Feb 17 2022 7:20:53 AM EST
Accepted by the SEC: Thu Feb 17 2022
Period: Saturday, February 12, 2022
Industry: Biological Products No Disgnostic Substances
  1. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: